C4 Therapeutics, Inc. Increase Decrease In Operating Lease Liability
C4 Therapeutics, Inc. (CCCC) reported Increase Decrease In Operating Lease Liability of -$3.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- C4 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.59M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.54M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.48M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.46M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$5.77M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$5.22M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$4.70M.
- C4 Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$507.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.12M 10-Q · filed 2026-08-11 | -$4.60M derived: sum of 3 quarters · filed 2026-08-11 | -$6.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$1.54M 10-Q · filed 2026-05-12 | -$3.02M derived: sum of 2 quarters · filed 2026-05-12 | -$4.48M derived: sum of 3 quarters · filed 2026-05-12 | -$5.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.94M derived: sum of 2 quarters · filed 2026-02-26 | -$4.38M derived: sum of 3 quarters · filed 2026-08-11 | -$5.77M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.90M derived: sum of 2 quarters · filed 2026-08-11 | -$4.29M 10-Q · filed 2025-11-06 | -$5.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.83M 10-Q · filed 2026-08-11 | -$4.17M derived: sum of 3 quarters · filed 2026-08-11 | -$5.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.39M 10-Q · filed 2026-05-12 | -$2.73M derived: sum of 2 quarters · filed 2026-05-12 | -$4.05M derived: sum of 3 quarters · filed 2026-05-12 | -$5.35M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.66M derived: sum of 2 quarters · filed 2026-02-26 | -$3.96M derived: sum of 3 quarters · filed 2026-02-26 | -$5.22M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.63M derived: sum of 2 quarters · filed 2025-11-06 | -$3.88M 10-Q · filed 2025-11-06 | -$5.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.56M 10-Q · filed 2025-08-07 | -$3.77M derived: sum of 3 quarters · filed 2025-08-07 | -$4.96M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.26M 10-Q · filed 2025-05-07 | -$2.46M derived: sum of 2 quarters · filed 2025-05-07 | -$3.65M derived: sum of 3 quarters · filed 2025-05-07 | -$4.83M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.40M derived: sum of 2 quarters · filed 2025-02-27 | -$3.57M derived: sum of 3 quarters · filed 2025-02-27 | -$4.70M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$2.37M derived: sum of 2 quarters · filed 2024-10-31 | -$3.49M 10-Q · filed 2024-10-31 | -$4.57M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.30M 10-Q · filed 2024-08-01 | -$3.38M derived: sum of 3 quarters · filed 2024-08-01 | -$1.82M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$1.12M 10-Q · filed 2024-05-08 | -$2.21M derived: sum of 2 quarters · filed 2024-05-08 | -$648.00K derived: sum of 3 quarters · filed 2024-05-08 | -$1.94M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $476.00K derived: sum of 2 quarters · filed 2024-02-22 | -$811.00K derived: sum of 3 quarters · filed 2024-02-22 | -$507.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $271.00K derived: sum of 2 quarters · filed 2023-11-01 | $575.00K 10-Q · filed 2023-11-01 | $459.00K derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$983.00K 10-Q · filed 2023-08-08 | -$1.10M derived: sum of 3 quarters · filed 2023-08-08 | -$1.36M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $304.00K 10-Q · filed 2023-05-04 | $188.00K derived: sum of 2 quarters · filed 2023-05-04 | -$76.00K derived: sum of 3 quarters · filed 2023-05-04 | -$333.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$380.00K derived: sum of 2 quarters · filed 2023-02-23 | -$637.00K derived: sum of 3 quarters · filed 2023-02-23 | -$888.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | -$264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$521.00K derived: sum of 2 quarters · filed 2022-11-03 | -$772.00K 10-Q · filed 2022-11-03 | -$1.00M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$508.00K 10-Q · filed 2022-08-04 | -$738.00K derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$251.00K 10-Q · filed 2022-05-05 | -$481.00K derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$881.00K 10-K · filed 2022-02-24 | ||
| 2020-09-30 | -$651.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | -$734.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |